Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nassim Nabbout

Hematology & Oncology Wichita, KS Medical Doctor

NPI 1528029147 CMS profile 23639

3243 E Murdock St, Suite 300, Wichita, KS 67208

Open in the dashboard

General payments

$28,102

1,518 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,022 paid to institutions, not to them · program year 2019

Through program year 2025, Nassim Nabbout of Wichita, KS is reported in the CMS Open Payments database as having received $28,102 across 1,518 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,022 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,372 175
2024 General $3,311 208
2023 General $3,543 225
2022 General $3,828 246
2021 General $5,533 249
2020 General $4,673 190
2019 General $3,842 225

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nassim Nabbout
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Nassim Nabbout were reported at $3,372. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Nassim Nabbout Hematology & Oncology median Middle half National median
2019 $3,842 $529 $121–$2,516 $163
2020 $4,673 $339 $82–$2,213 $114
2021 $5,533 $263 $49–$1,965 $132
2022 $3,828 $416 $103–$2,395 $149
2023 $3,543 $542 $125–$2,646 $160
2024 $3,311 $692 $141–$3,008 $164
2025 $3,372 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,383 139 payments
  2. Pfizer Inc. $1,765 154 payments
  3. E.R. Squibb & Sons, L.L.C. $1,728 155 payments
  4. Rigel Pharmaceuticals, Inc. $1,078 15 payments
  5. Merck Sharp & Dohme Corporation $1,068 66 payments
  6. AstraZeneca Pharmaceuticals LP $1,056 51 payments
  7. Genentech USA, Inc. $1,021 54 payments
  8. Amgen Inc. $1,014 60 payments
  9. Dova Pharmaceuticals $1,005 3 payments
  10. Seattle Genetics, Inc. $915 43 payments
  11. Other $15,069 778 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $23,834 1,464 payments
  2. Consulting Fee $2,125 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $850 1 payment
  4. Education $694 44 payments
  5. Long term medical supply or device loan $598 6 payments
Products named General payments · program years 2019–2025
  1. KISQALI $1,197 38 payments
  2. Doptelet $1,169 11 payments
  3. Tavalisse $1,078 15 payments
  4. KEYTRUDA $935 58 payments
  5. OPDIVO $911 87 payments
  6. XPOVIO $860 7 payments
  7. IBRANCE $732 60 payments
  8. Trelstar $500 1 payment
  9. ADCETRIS $496 28 payments
  10. LIBTAYO $453 27 payments
  11. Other $25,537 1,612 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

2,668

Median for Hematology-Oncology: 604

Drug cost

$5,216,027

Median for Hematology-Oncology: $1,306,514

Branded share of claims

25%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jakafi Ruxolitinib Phosphate Brand 65 $965,336
Revlimid Lenalidomide Brand 35 $691,285
Calquence Acalabrutinib Maleate Brand 40 $626,121
Xtandi Enzalutamide Brand 31 $430,383
Venclexta Venetoclax Brand 30 $314,098
Tasigna Nilotinib Hcl Brand 16 $307,723
Xalkori Crizotinib Brand 13 $283,441
Cabometyx Cabozantinib S-Malate Brand 11 $282,848
Lenvima Lenvatinib Mesylate Brand 11 $268,582
Tagrisso Osimertinib Mesylate Brand 12 $204,049

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 235 billing codes

Paid by Medicare

$9,007,406

Of which drugs: $8,450,404

Medicare patients

1,353

Average age 75

Services billed

475,168

746 women, 607 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 54%
Arthritis 38%
Diabetes 34%
Ischemic heart disease 30%
Chronic kidney disease 30%
Atrial fibrillation 24%
COPD 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 64 43,300 $1,926,023
Injection, nivolumab, 1 mg J9299 Office 27 33,420 $822,333
Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 Office 22 14,580 $576,600
Injection, ipilimumab, 1 mg J9228 Office 13 2,700 $370,066
Injection, durvalumab, 10 mg J9173 Office 12 4,714 $299,735
Injection, atezolizumab, 10 mg J9022 Office 13 4,512 $294,495
Injection, denosumab, 1 mg J0897 Office 77 12,840 $261,055
Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg Q5129 Office 22 4,030 $208,305
Injection, romiplostim, 10 micrograms J2796 Office 14 2,430 $187,217
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 Office 25 4,360 $160,516

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 78 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPDIVO
$145 — 33,420
VENCLEXTA
$145 30 —
REBLOZYL
$136 — —
ENHERTU
$121 — —
Fabhalta
$118 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 78 with Patron

Records

1,518 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record